Navigation Links
For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Date:4/30/2013

BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their prescribing decisions when treating Clostridium difficile infections (CDIs). Similarly, surveyed hospital pharmacy directors indicate a high willingness to grant favorable formulary status to therapies that can demonstrate a decrease in recurrence rates of CDIs. However, even though clinical data and interviewed key opinion leaders indicate that emerging therapies provide a significant advantage over current standard-of-care therapies, marketers will need to be cognizant of price in a CDI market dominated by inexpensive and efficacious alternatives.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Market Opportunity Awaits Therapies That Provide Low Rates of CDI Recurrences finds that surveyed U.S. infectious disease specialists would prescribe Cubist's surotomycin to 15 percent of their CDI patients, driven mostly by surotomycin's lower rate of CDI recurrence relative to oral vancomycin (ViroPharma's Vancocin; generics). However, Decision Resources forecasts that surotomycin will earn a more-modest patient share of 5 percent, constrained partially by continued uptake of fidaxomicin (Optimer/Cubist's Dificid; Astellas' Dificlir), which has already demonstrated superiority in recurrence rates over oral vancomycin.

"Uptake of surotomycin will likely be constrained, unless it can demonstrate either higher clinical efficacy than Dificid or offer more favorable pricing", said Decision Resources Analyst Maria Ascano Ph.D. "Other factors that will also limit surotomycin's uptake are competition from other emerging therapies like cadazolid (Actelion) and MK-3415A (Merck), generic entry of oral vancomycin capsules, and the continued use of oral preparations of IV vancomycin."

Nevertheless, surveyed hospital pharmacy directors are highly willing to grant favorable formulary inclusion to therapies that provide increased clinical cure rates, particularly in CDI patients that suffer from severe and/or recurrent infections. As a result, market opportunity awaits therapies that can demonstrate higher overall clinical efficacy in patients with difficult-to-treat CDIs.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
4. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
5. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
6. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
7. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
8. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
9. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
10. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
11. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 Summary ... deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605675-summary/view-report.html Description The Global Atherosclerosis ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... disease partnering deals and agreements entered into by the ... http://www.reportlinker.com/p03605682-summary/view-report.html Description The Global Motor Neurone ... understanding and access to partnering deals and agreements entered ... - Trends in partnering deals - Top deals ...
(Date:2/22/2017)... ALBANY, New York , February 22, 2017 ... leading the global automated microscopy market are Olympus ... companies held a share or 75% in the ... likely to witness tremendous product innovation through result-oriented ... Several players are also expected to focus on ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... services to the largest network of hospitals, health information exchanges, physicians and patients, ... Health Information Technology (ONC-HIT) 2015 Edition Health IT Module Certification via Drummond Group ...
(Date:2/22/2017)... ... , ... South Bend’s Lunkerville, the award-winning TV series that catches real people ... (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate through ... to Lake Denmark, New Jersey, to fish with war veteran Justin Vail from the ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... Fla. (PRWEB) , ... February 22, 2017 , ... ... is just as effective on smaller and sometimes harder to reach ones, according ... were presented at the International Stroke Conference in Houston by Ricardo A. Hanel, ...
(Date:2/22/2017)... ... 2017 , ... Sideline Products participated in the World Horse Expo held in ... and his production crew. Tom Seay’s program “Best of America by Horseback” is ... Sidekicks will be featured on April 6, 2017. After the broadcast, the clip will ...
Breaking Medicine News(10 mins):